{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:51Z","timestamp":1790958291670,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"AstraZeneca"},{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      To use the Archimedes model to estimate the consequences of delays in oral antidiabetic drug (\n                      <jats:styled-content style=\"fixed-case\">OAD<\/jats:styled-content>\n                      ) treatment intensification on glycaemic control and long\u2010term outcomes at 5 and 20\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Using real\u2010world data, we modelled a cohort of hypothetical patients with glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ) \u22658%, on metformin, with no history of insulin use. The cohort included 3 strata based on the number of\n                      <jats:styled-content style=\"fixed-case\">OADs<\/jats:styled-content>\n                      taken at baseline. The first add\u2010on in the intensification sequence was a sulphonylurea, next was a dipeptidyl peptidase\u20104 inhibitor, and last, a thiazolidinedione. The scenarios included either no delay or delay, based on observed and extrapolated times to intensification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 1\u2009year,\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      was 6.8% for patients intensifying without delay, and 8.2% for those delaying intensification. For no delay vs delay, risks of major adverse cardiac events, myocardial infarction, heart failure and amputations were reduced by 18.0%, 25.0%, 13.7%, and 20.4%, respectively, at 5\u2009years; severe hypoglycaemia risk, however, increased to 19% for the no delay scenario vs 12.5% for delay. At 20\u2009years, the results showed similar trends to those at 5\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Timing of intensification of\n                      <jats:styled-content style=\"fixed-case\">OAD<\/jats:styled-content>\n                      therapy according to guideline recommendations led to greater reductions in\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      and lower risks of complications, but higher risks of hypoglycaemia than delaying intensification. These results highlight the potential impact of timely treatment intensification on long\u2010term outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12913","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T07:56:41Z","timestamp":1487318201000},"page":"1006-1013","source":"Crossref","is-referenced-by-count":13,"title":["Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control:\n                    <scp>A<\/scp>\n                    n individual patient simulation study"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-492X","authenticated-orcid":false,"given":"Henry J.","family":"Folse","sequence":"first","affiliation":[{"name":"Evidera  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanti","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb  Wallingford Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Sheehan","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals  Fort Washington Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Ward","sequence":"additional","affiliation":[{"name":"Evidera  Lexington Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Pelkey","sequence":"additional","affiliation":[{"name":"Evidera  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan A.","family":"Dinh","sequence":"additional","affiliation":[{"name":"Evidera  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"AstraZeneca, One MedImmune Way  Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kim","sequence":"additional","affiliation":[{"name":"AstraZeneca, One MedImmune Way  Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-9-200111060-00012"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.7.1535"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1749"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.03.06.dc05-1937"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0139-y"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0331"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.06.004"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12683"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3093"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3102"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0521"},{"key":"e_1_2_6_14_1","unstructured":"CDC\/National Center for Health Statistics.National Health and Nutrition Examination Survey data.1999\u20102008.http:\/\/www.cdc.gov\/nchs\/nhanes.htm. Accessed March 2013."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-4-200508160-00006"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9022"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9019"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62162-0"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.952716"},{"issue":"10","key":"e_1_2_6_20_1","first-page":"551","article-title":"Comparative evaluation of diabetic and non\u2010diabetic stroke\u2013effect of glycaemia on outcome","volume":"102","author":"Sarkar R","year":"2004","journal-title":"J Indian Med Assoc"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00885.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051594"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0260-x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2675"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13062"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2018"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12000"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9400"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2014.01.017"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2568"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506115"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0088-z"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000782"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:45:46Z","timestamp":1761860746000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/dom.12913"],"URL":"https:\/\/doi.org\/10.1111\/dom.12913","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]}}}